Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Expands its antibody drug pipeline using GenScript Bio’s Berkeley Lights Beacon platform.
December 9, 2020
By: Contract Pharma
Contract Pharma Staff
On December 7, 2020, GenScript ProBio and Initium Therapeutics announced that Initium Therapeutics has launched a single B-cell based antibody development platform through collaboration with GenScript ProBio. Initium Therapeutics is a US biotechnology company, a spin-off from South Korean biotech company Tiumbio, seeking antibody-based therapeutics for patients who are suffering from unaddressed incurable and rare diseases. Goals of the Partnership The strategic collaboration between the two companies will allow Initium Therapeutics to expand their antibody drug pipeline using GenScript ProBio’s ultra-rapid, high-efficient Berkeley Lights Beacon platform. Furthermore, their partnership will potentially be extended to GenScript ProBio’s cutting edge therapeutic antibody development platforms, including bispecific antibody platform, human antibody transgenic mouse and/or downstream therapeutic antibody development and manufacturing processes. Through this partnership, Initium Therapeutics expects to significantly accelerate their therapeutic antibody pipeline development. “We are very pleased to announce that through the strategic collaboration with GenScript ProBio, we will expand our therapeutic antibody pipeline in fibrosis, immuno-oncology and hemophilia,” commented Dr. Huntaek Kim, CEO of Initium Therapeutics/TiumBio. “Initium Therapeutics was established to develop innovative antibody-based therapeutics focusing on unaddressed rare diseases. Our deep scientific and drug development expertise have allowed us to recognize new therapeutic targets in fibrosis, immuno-oncology and hemophilia, and I believe the partnership with GenScript ProBio will strengthen our therapeutic antibody platform and expand our antibody pipeline in more rapid and highly efficient ways.” “We are very glad to cooperate with Initium Therapeutics and help them expand their therapeutic antibody pipeline in fibrosis, immuno-oncology and hemophilia by utilizing GenScript ProBio’s Berkeley Lights Beacon platform,” said Dr. Brian Min, CEO of GenScript ProBio. “Our Single B cell screening platform dramatically expedites and enables unparalleled B cell diversity. We will continue fueling Initium’s first-rate research capabilities and look forward to further collaboration to bring diverse treatment options to patients in rare diseases,” he added.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !
